(Q40044837)

16 September 2017

1 reference

title

Absorption, distribution, excretion and fate of kanamycin (English)

1 reference

history and philosophy of science

16 September 2017

main subject

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

3 May 2023

author name string

C. M. Kunin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A5336394

3 May 2023

language of work or name

English

0 references

publication date

1 June 1966

1 reference

full work available at URL

16 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.1966.tb42999.x

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1749-6632.1966.tb42999.x/fullpdf

3 May 2023

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Annals of the New York Academy of Sciences

3 May 2023

published in

1 reference

16 September 2017

volume

132

1 reference

16 September 2017

issue

2

1 reference

16 September 2017

page(s)

811-818

1 reference

THE USE OF POTENTIALLY NEPHROTOXIC ANTIBIOTICS IN THE TREATMENT OF GRAM-NEGATIVE INFECTIONS IN UREMIC PATIENTS.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1966.TB42999.X

Laboratory studies with kanamycin

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Kanamycin for bowel sterilization

3 May 2023

2

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease

3 May 2023

3

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

In vitro and pharmacological studies with kanamycin

3 May 2023

8

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Clinical experiences with kanamycin.

3 May 2023

9

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Kanamycin serum levels in infants and children

3 May 2023

10

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Kanamycin: pharmacological, microbiological, and clinical observations

3 May 2023

11

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Kanamycin in the treatment of infections in infants and children

3 May 2023

12

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Clinical and laboratory studies with kanamycin

3 May 2023

13

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Pharmacological studies with kanamycin

3 May 2023

14

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Pancreatic Secretion of Antibacterial Agents Through a New Pancreatic Fistula in the Dog

3 May 2023

18

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin

3 May 2023

19

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1966.TB42999.X

3 May 2023

Identifiers

1 reference

16 September 2017

1 reference